Trial Profile

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neldaleucel (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms APOLLO
Sponsors Marker Therapeutics Inc

Most Recent Events

26 Aug 2025 According to a Marker Therapeutics media release, company is looking forward to advancing the study to the dose expansion phase. Another data update in the first half of 2026.
26 Aug 2025 Results presented in the Media Release
20 May 2025 Results presented in a Marker Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com